Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

3 results
6:24 PM, Jan 27, 2016  |  BC Extra | Company News

Merck, CRT in deal for PRMT5 inhibitors

including the epigenetic control of p53 and other genes. It is one of over 20 histone methyltransferases
6:02 PM, Apr 26, 2012  |  BC Extra | Company News

Celgene, Epizyme in epigenetic deal

partnered with Epizyme Inc. (Cambridge, Mass.) to discover, develop and commercialize cancer therapeutics that inhibit histone methyltransferases
for an initial three years, with a potential one-year extension. The deal does not include histone methyltransferases
months. In January 2011, Epizyme partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for therapeutics targeting undisclosed histone methyltransferases
6:24 PM, Jan 10, 2011  |  BC Extra | Company News

GSK, Epizyme in histone methyltransferases deal

partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases